Evidence map›Paper›PMID 36632563›Full record

ArticleOncoimmunology2023

Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas.

Nicole L Edmonds, Sarah E Gradecki, Priya Katyal, Kevin T Lynch, Anne M Stowman, Alejandro A Gru, Victor H Engelhard, Craig L Slingluff, Ileana S Mauldin

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Nicole L EdmondsSchool of Medicine, University of Virginia, Charlottesville, VA, USA.
Sarah E GradeckiDepartment of Pathology, University of Virginia Health System, Charlottesville, VA, USA.
Priya KatyalDepartment of Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Kevin T LynchDepartment of Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Anne M StowmanDepartment of Pathology, University of Vermont Medical Center, Burlington, VA, USA.
Alejandro A GruDepartment of Pathology, University of Virginia Health System, Charlottesville, VA, USA.
Victor H EngelhardDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Craig L SlingluffDepartment of Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Ileana S MauldinDepartment of Surgery, University of Virginia Health System, Charlottesville, VA, USA.
University of Virginia Health System · USCarter Center · USUniversity of Vermont Medical Center · USUniversity of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Cardiovascular Surgery Training ProgramT32HL007849 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KRON, IRVING L., LAUBACH, VICTOR E · 1998 to 2025
$7.0M
Supplement - Manipulating microenvironment and vasculature to enhance T cell infiltration into tumorsR01CA233716 · NCI · UNIVERSITY OF VIRGINIA · PI ENGELHARD, VICTOR H, KELLY, KIMBERLY A. · 2019 to 2023
$2.9M
Phase I Designs for Combined Immunotherapies in CancerK25CA181638 · NCI · UNIVERSITY OF VIRGINIA · PI WAGES, NOLAN · 2014 to 2018
$780k
Lymph node-like vasculature and naive T cell infiltration into tumorsR21CA181794 · NCI · UNIVERSITY OF VIRGINIA · PI ENGELHARD, VICTOR H · 2015 to 2016
$378k
NCI NIH HHS K25 CA181638NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA233716NCI NIH HHS R21 CA181794NHLBI NIH HHS T32 HL007849
6 · The paper itself

Abstract

Tertiary lymphoid structures (TLS) are ectopic lymphoid structures that can arise in human cancers and are associated with improved overall survival (OS) and response to immune checkpoint blockade (ICB) in several cancers, including non-desmoplastic metastatic melanoma (NDMM). Desmoplastic melanoma (DM) has one of the highest response rates to ICB, and we previously identified that primary DM (PDM) contains TLS. Despite the association of TLS with survival and ICB response, it is unknown whether TLS or associated markers of immune activity can differ between PDM and NDMM. We hypothesized that PDM would contain higher frequencies of TLS than NDMM, that T and B-cell densities and proliferation would be greater in TLS of PDM than TLS of NDMM, and that proliferation rates of T and B-cells in PDM TLS would be concordant with those of intratumoral lymphocytes. We found that four features of TLS in PDM distinguish them from TLS in NDMM. TLS were peritumoral in NDMM but intratumoral in PDM. CD8

Indexed as

CD8-Positive T-LymphocytesMelanomaTertiary Lymphoid StructuresBiomarkersCell ProliferationHumansBiomarkersdesmoplastic melanomaImmunologymelanomamultiplex immunofluorescence histologytertiary lymphoid structurestumor infiltrating lymphocytes

Identifiers

PMID36632563
PMCPMC9828737
OpenAlexW4313706956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.